2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-133970
    5α-Cholestane 481-21-0 99.34%
    5α-Cholestane is a skeleton. 5α-Cholestane can be used in the synthesis of Brassinosteroids. 5α-Cholestane can be used in skeletal muscle research.
    5α-Cholestane
  • HY-134421
    2-Butenoyl coenzyme A lithium 102680-35-3 98%
    2-Butenoyl coenzyme A lithium is an inactivator and a substrate of Plasmodium falciparum enoyl-β-hydroxyacyl-acyl carrier protein (ACP) reductase and other enoyl-CoA reductases, and it is also the lithium salt of trans-2-methyl-2-butenoyl coenzyme A. 2-Butenoyl coenzyme A lithium acts on short-chain and medium-chain coenzyme A dehydrogenases as well as glutaryl-CoA dehydrogenase, and shows no activity against wild-type isovaleryl-CoA dehydrogenase. 2-Butenoyl coenzyme A lithium functions as a metabolite in the L-isoleucine catabolic pathway, and can serve as a substrate in the activity assay of 3-ketothiolase. 2-Butenoyl coenzyme A lithium is applicable to research related to 3-ketothiolase deficiency.
    2-Butenoyl coenzyme A lithium
  • HY-135767
    Bicyclopyrone 352010-68-5 99.95%
    Bicyclopyrone is an inhibitor of 4-hydroxyphenylpyruvate dioxygenase (Hpd).
    Bicyclopyrone
  • HY-139793
    UDP-glucosamine disodium 1355005-51-4 98%
    UDP-glucosamine (UDP-GlcNAc) disodium is a substrate for O-GlcNAc transferase, which catalyzes the attachment of O-GlcNAc to proteins. O-GlcNAcase catalyzes the removal of O-GlcNAc from proteins. UDP-glucosamine (UDP-GlcNAc) disodium is the end product of the hexosamine biosynthesis pathway, which is regulated primarily by glucose-6-phosphate-Glutamine:fructose-6-phosphate amidotransferase (GFAT).
    UDP-glucosamine disodium
  • HY-143201
    DS20362725 2735803-20-8 99.34%
    DS20362725 is an estrogen-related receptor α (ERRα) agonist. DS20362725 inhibits the binding between receptor-interacting protein 140 (RIP140) corepressor peptide (10 nM) and GST-ERRα ligand-binding domain (LBD; 1.2 μM) with an IC50 value of 0.6 μM. DS20362725 can be used for the research of metabolic disorders, including type 2 diabetes mellitus (T2DM).
    DS20362725
  • HY-144765
    NF-κB-IN-4 3033258-60-2 98.51%
    NF-κB-IN-4 (compound 17) is a potent NF-κB pathway inhibitor with blood brain barrier (BBB) permeability. NF-κB-IN-4 exhibits potential anti-neuroinflammatory activity with low toxicity. NF-κB-IN-4 can block the activation and phosphorylation of IκBα, reduce expression of NLRP3, and thus inhibit NF-κB activation. NF-κB-IN-4 can be used for neuroinflammation related diseases research.
    NF-κB-IN-4
  • HY-146725
    FBPase-IN-1 20362-54-3 98.07%
    FBPase-IN-1 is a potent FBPase (Fructose-1,6-bisphosphatase) inhibitor for Type 2 diabetes (T2D) study with an IC50 of 0.22 μM. FBPase-IN-1 can reduce blood glucose levels and ameliorate glucose tolerance. FBPase-IN-1 modifies the C128 site, regulates the N125-S124-S123 allosteric pathway of FBPase and affects the catalytic activity of FBPase.
    FBPase-IN-1
  • HY-147379
    Hepcidin antagonist-1 338965-09-6 98.07%
    Hepcidin antagonist-1 (example 104) is a potent hepcidin (hepcidine) antagonist with an IC50<50 μM. Hepcidin antagonist-1 can be used for researching iron metabolism disorders, such as anemias.
    Hepcidin antagonist-1
  • HY-15209S
    Repaglinide-d5 1217709-85-7 98.67%
    Repaglinide-d5 is deuterium labeled Repaglinide. Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus.
    Repaglinide-d5
  • HY-153815
    GLP-1 receptor agonist 11 2784590-83-4 99.25%
    GLP-1 receptor agonist 11 (compound 3) is an agonist of GLP Receptor. GLP-1 receptor agonist 11 can be used in the study of diseases such as diabetes and non-alc. fatty liver disease.
    GLP-1 receptor agonist 11
  • HY-156119
    MLKL-IN-6 3080148-24-6 98.57%
    MLKL-IN-6 (compound P28) is a mixed lineage kinase inhibitor targeting Mixed Lineage Kinase domain-like (MLKL). MLKL-IN-6 inhibits cell necrosis. MLKL-IN-6 inhibits MLKL phosphorylation and oligomerization during cell necrosis, inhibits immune cell death, and reduces the expression of adhesion factors. MLKL-IN-6 has low cytotoxicity, and it inhibits hepatic stellate cell activation, reduces liver fibrosis marker levels, and has anti-fibrotic effects.
    MLKL-IN-6
  • HY-16343C
    NB-598 Maleate 155294-62-5
    NB-598 Maleate is a potent and competitive inhibitor of squalene epoxidase (SE), and suppresses triglyceride biosynthesis through the farnesol pathway. NB-598 (Maleate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    NB-598 Maleate
  • HY-164595
    IHMT-MST1-39 2414484-01-6 99.68%
    IHMT-MST1-39 is an orally active inhibitor for MST kinase, with IC50 of 42, 109, 286, 159 nM for MST1, MST2, MST3, MST4. IHMT-MST1-39 activates the AMPK signaling pathway in liver cells, reduces apoptosis of pancreatic β-cells. IHMT-MST1-39 can be used for the studies of type 1 diabetes (T1D) and type 2 diabetes (T2D).
    IHMT-MST1-39
  • HY-167935
    LCC-12 formic 3029253-76-4 99.85%
    LCC-12 formic is a dimer of metformin that targets mitochondrial copper(II), leading to a decrease in the NAD(H) pool and modulation of inflammatory responses. LCC-12 formic reduces inflammation in mouse models of bacterial and viral infections. LCC-12 formic also serves as a tool for investigating metabolic diseases through its effects on cell plasticity and epigenetic programming.
    LCC-12 formic
  • HY-169380
    PARL-IN-2 3099681-58-7 99.80%
    PARL-IN-2 (Compound 14) is a covalent inhibitor of the mitochondrial intramembrane protease PARL with an EC50 value of 0.16 μM. PARL-IN-2 leads to a robust activation of the PINK1/Parkin pathway. PARL-IN-2 promotes PINK1/Parkin-dependent mitophagy.
    PARL-IN-2
  • HY-169789
    PKN3-IN-1 2361545-75-5 98.97%
    PKN3-IN-1 (compound 16) inhibits PKN3 (serine/threonine protein kinase 3) and GAK (cyclin G-associated kinase) with IC50 of 0.014 μM and Ki of 0.0044 μM respectively. PKN3-IN-1 is a potential tool compound to study the cell biology of PKN3 and its role in pancreatic and prostate cancer and T-cell acute lymphoblastic leukemia .
    PKN3-IN-1
  • HY-172741
    Dioctanoyl PI(3,5)P2 sodium 98.7%
    Dioctanoyl PI(3,5)P2 sodium is a synthetic analog of PI(3,5)P2 (a natural phosphatidylinositol). Phosphatidylinositol phosphates (PIPs) are intracellular amphiphilic molecules implicated in numerous cellular responses including growth, division, movement, differentiation, neuro-exocytosis, and survival.
    Dioctanoyl PI(3,5)P2 sodium
  • HY-17504R
    Rosuvastatin Calcium (Standard) 147098-20-2 99.94%
    Rosuvastatin (Calcium) (Standard) is the analytical standard of Rosuvastatin (Calcium). This product is intended for research and analytical applications. Rosuvastatin Calcium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Calcium potently blocks hERG current with an IC50 of 195 nM. Rosuvastatin Calcium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Calcium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.
    Rosuvastatin Calcium (Standard)
  • HY-175739
    TFAM activator 1 932992-44-4 99.25%
    TFAM activator 1 is a TFAM activator. TFAM activator 1 increases TFAM protein levels, promotes mitochondrial DNA stability, increases mitochondrial DNA copy number, and prevents mitochondrial DNA from escaping into the cytoplasm. TFAM activator 1 improves cellular energy metabolism in cybrid cells. TFAM activator 1 reduces fibrosis markers in fibroblasts. TFAM activator 1 can be used in the research of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes syndrome, systemic sclerosis, and autoimmune diseases.
    TFAM activator 1
  • HY-34740S
    Ethylmalonic acid-d3 70907-93-6 98.0%
    Ethylmalonic acid-d3 is the deuterium labeled Ethylmalonic acid (HY-34740). Ethylmalonic acid is a short-chain organic dicarboxylic acid. Ethylmalonic acid synergistically induces mitochondrial permeability transition (MP) with Ca2+, inhibits Mi-CK, and disrupts mitochondrial energy metabolism. Ethylmalonic acid can be used in the research of SCADD, EE and other genetic metabolic diseases characterized by EMA accumulation.
    Ethylmalonic acid-d3
Cat. No. Product Name / Synonyms Application Reactivity